title: FDA approves new agent for multiple myeloma.
authors.forename: Marilyn P
authors.initials: MP
authors.lastname: Fenichel
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D009842:Oligopeptides / Q000008:administration & dosage; D000077767:Panobinostat; D011719:Pyrazines / Q000008:administration & dosage; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D006877:Hydroxamic Acids; D007211:Indoles; D009842:Oligopeptides; D011719:Pyrazines; D000069286:Bortezomib; C524865:carfilzomib; D003907:Dexamethasone; D000077767:Panobinostat